Novel drug candidates targeting Toxoplasma gondii in maternal–fetal interface models
Taken together, our findings support the potential of MMV675968, MMV022478, and MMV021013 as promising drug candidates for the treatment of congenital toxoplasmosis. MMV021013 stands out as the most promising compound, combining high predicted gastrointestinal (GI) absorption and blood-brain barrier (BBB) permeability, with no predicted mutagenic, tumorigenic, irritant, or reproductive effects.
Authors
- Rosiane Nascimento Alves (ORCID: https://orcid.org/0000-0001-7470-7082)
- Bellisa Freitas Barbosa (ORCID: https://orcid.org/0000-0003-4611-2844)
- Marina Paschoalino
- Matheus Carvalho Barbosa
- Marcos Paulo Oliveira Almeida (ORCID: https://orcid.org/0000-0003-3835-1925)
- Juliana Quero Reimão (ORCID: https://orcid.org/0000-0002-4418-0838)
- Guilherme Vieira Faria (ORCID: https://orcid.org/0000-0002-6813-2080)
- Guilherme de Souza (ORCID: https://orcid.org/0000-0003-0787-9719)
- Samuel Cota Teixeira (ORCID: https://orcid.org/0000-0002-1978-1658)
- Eloísa Amália Vieira Ferro (ORCID: https://orcid.org/0000-0002-7447-2583)
- Joed Pires de Lima Júnior (ORCID: https://orcid.org/0000-0001-6886-281X)
- Rafael Oliveira (ORCID: https://orcid.org/0000-0002-1608-9172)
- Natália Carine Lima dos Santos (ORCID: https://orcid.org/0000-0003-1660-3423)
- Angélica Oliveira Gomes
Institutions
- Universidade do Estado de Minas Gerais (BR)
- Universidade Federal do Triângulo Mineiro (BR)
- Faculdade de Medicina de Jundiaí (BR)
- Universidade Federal de Uberlândia (BR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.3389/fphar.2025.1673462
- Primary Topic
- Toxoplasma gondii Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medicines for Malaria Venture